48 related articles for article (PubMed ID: 10561260)
1. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Vasey PA; Paul J; Birt A; Junor EJ; Reed NS; Symonds RP; Atkinson R; Graham J; Crawford SM; Coleman R; Thomas H; Davis J; Eggleton SP; Kaye SB
J Clin Oncol; 1999 Jul; 17(7):2069-80. PubMed ID: 10561260
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer.
You ZY; Wu MF; Li H; Ye YF; Wang LJ; Lin ZQ; Li J
J Gynecol Oncol; 2024 Jan; 35(1):e1. PubMed ID: 37477105
[TBL] [Abstract][Full Text] [Related]
3. Curative treatment in a patient with gastric cancer stage IV: a case report.
Diel A; Rodermann E; Kienzle HF; Meuthen D; Meuthen I
F1000Res; 2012; 1():34. PubMed ID: 24358825
[TBL] [Abstract][Full Text] [Related]
4. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
6. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Wagner U; Marth C; Largillier R; Kaern J; Brown C; Heywood M; Bonaventura T; Vergote I; Piccirillo MC; Fossati R; Gebski V; Lauraine EP
Br J Cancer; 2012 Aug; 107(4):588-91. PubMed ID: 22836511
[TBL] [Abstract][Full Text] [Related]
7. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
[TBL] [Abstract][Full Text] [Related]
8. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Berek JS; Renz M; Kehoe S; Kumar L; Friedlander M
Int J Gynaecol Obstet; 2021 Oct; 155 Suppl 1(Suppl 1):61-85. PubMed ID: 34669199
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.
Subramanian S; Samar A; Joshi N; Sejpal J; Khan MA; Ahmad I
Mol Clin Oncol; 2021 Aug; 15(2):162. PubMed ID: 34194740
[TBL] [Abstract][Full Text] [Related]
10. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy Resistance in Advanced Ovarian Cancer Patients.
Pokhriyal R; Hariprasad R; Kumar L; Hariprasad G
Biomark Cancer; 2019; 11():1179299X19860815. PubMed ID: 31308780
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.
Tian J; Min Y; Rodgers Z; Wan X; Qiu H; Mi Y; Tian X; Wagner KT; Caster JM; Qi Y; Roche K; Zhang T; Cheng J; Wang AZ
Nanomedicine; 2017 Apr; 13(3):1301-1307. PubMed ID: 27884641
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.
Muenyi CS; Trivedi AP; Helm CW; States JC
Toxicol Sci; 2014 May; 139(1):74-82. PubMed ID: 24519527
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer.
Isonishi S; Suzuki M; Nagano H; Takagi K; Shimauchi M; Kawabata M; Ochiai K
J Gynecol Oncol; 2013 Apr; 24(2):154-9. PubMed ID: 23653833
[TBL] [Abstract][Full Text] [Related]
16. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.
Araki K; Kitagawa K; Mukai H; Mukohara T; Kodama K; Ando Y; Narabayashi M; Minami H; Mera K; Sasaki Y
Invest New Drugs; 2012 Dec; 30(6):2327-33. PubMed ID: 22139065
[TBL] [Abstract][Full Text] [Related]
17. Adaptive therapy.
Gatenby RA; Silva AS; Gillies RJ; Frieden BR
Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
[TBL] [Abstract][Full Text] [Related]
18. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.
Silvani A; Gaviani P; Fiumani A; Scaioli V; Lamperti E; Eoli M; Botturi A; Salmaggi A
J Neurooncol; 2009 Oct; 95(1):61-64. PubMed ID: 19381446
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
Park SH; Cho EK; Bang SM; Shin DB; Lee JH; Lee YD
BMC Cancer; 2005 Feb; 5():21. PubMed ID: 15723709
[TBL] [Abstract][Full Text] [Related]
20. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.
Guastalla JP; Diéras V
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S16-22. PubMed ID: 14661042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
